Kaleido Biosciences, Inc. announced unaudited consolidated earnings results for the second Quarter and Six Months Ended June 30, 2021. For the quarter, the company reported collaboration revenue of $211,000 compared to $250,000 a year ago. Loss from operations of $23,207,000 against $18,142,000 a year ago. Net loss was $23,889,000 compared to $18,922,000 a year ago. Net loss per share—basic and diluted was $0.56 against $0.59 a year ago. For the six months, the company reported collaboration revenue of $508,000 compared to $250,000 a year ago. Loss from operations of $45,555,000 against $37,196,000 a year ago. Net loss was $46,931,000 compared to $38,473,000 a year ago. Net loss per share—basic and diluted was $1.14 against $1.24 a year ago.